Related Experiment Video
Updated: Oct 3, 2025

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
Published on: June 26, 2018
COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases
Borja Del Carmelo Gracia1, Luis Sáez2, Lucio Pallarés3
1Sytemic Autoimmune Diseases Unit, Internal Medicine Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain.
Insights
Individuals with systemic autoimmune diseases (SAD) on anti-TNF-alpha therapy had a significantly higher risk of SARS-CoV-2 infection. However, COVID-19 cases in this population were generally mild.
Area of Science:
- Rheumatology
- Immunology
- Infectious Diseases
Background:
- Outcomes of COVID-19 in patients with systemic autoimmune diseases (SAD) are not well-defined.
- Understanding risk factors for SARS-CoV-2 infection in rheumatic disease populations is crucial.
Purpose of the Study:
- To investigate demographic and clinical factors associated with COVID-19 infection in individuals with rheumatic diseases.
- To analyze the impact of specific treatments on SARS-CoV-2 infection risk in SAD patients.
Main Methods:
- A two-phase cross-sectional survey was conducted in April and October 2020.
- Data collected included COVID-19 infection status, disease severity, demographics, comorbidities, and medications.
- Multivariate analysis was used to identify associated factors.
Main Results:
- 1,529 individuals with autoimmune disease diagnoses were included; 50 tested positive for SARS-CoV-2.
- Anti-TNF-alpha treatment was significantly associated with an increased risk of infection (OR 3.422, p=0.011).
- A trend towards increased risk was observed with mycophenolate treatment (OR 2.016, p=0.094).
Conclusions:
- Anti-TNF-alpha therapy is linked to a greater than threefold risk of SARS-CoV-2 infection, though infections were mild.
- The cumulative incidence of COVID-19 in patients with SAD may be higher than in the general population.
- Significant variations in infection risk exist among different autoimmune diseases.
Objectives:
COVID-19 outcomes in population with systemic autoimmune diseases (SAD) remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 infection in people with rheumatic disease.
Methods:
Two phases cross-sectional survey of individuals with rheumatic disease in April 2020 and October 2020. COVID infection, severity of disease, age, sex, smoking status, underlying rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analyzed.
Results:
A total of 1,529 individuals with autoimmunity disease diagnosis were included. Out of 50 positive patients, 21 required telephone medical assistance, 16 received assessment by primary care physician, 9 were evaluated in Emergency Department and 4 patient required hospitalization. Multivariate analysis was performed without obtaining differences in any of the systemic autoimmune diseases. Regarding the treatments, significant differences were found (p 0.011) in the treatment with anti-TNF-alpha agents with OR 3.422 (1.322-8.858) and a trend to significance (p 0.094) was observed in patients receiving mycophenolate treatment [OR 2.016 (0.996-4-081)].
Conclusions:
Anti-TNF-alpha treatment was associated with more than 3-fold risk of suffering from SARS-CoV-2 infection, although in all cases infection was mild. Cumulative incidence in patients with SAD was up to 5 times higher than general population but with great differences between autoimmune diseases.
More Related Videos
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Myocarditis II: Clinical Features and Diagnostic Tests
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Rheumatic Heart Disease I: Introduction

